Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Gross Margin (2018 - 2025)

Historic Gross Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 14.85%.

  • BioNexus Gene Lab's Gross Margin rose 24300.0% to 14.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.77%, marking a year-over-year increase of 13100.0%. This contributed to the annual value of 13.56% for FY2024, which is 500.0% down from last year.
  • BioNexus Gene Lab's Gross Margin amounted to 14.85% in Q3 2025, which was up 24300.0% from 16.28% recorded in Q2 2025.
  • BioNexus Gene Lab's Gross Margin's 5-year high stood at 19.83% during Q3 2021, with a 5-year trough of 10.62% in Q2 2022.
  • In the last 5 years, BioNexus Gene Lab's Gross Margin had a median value of 14.62% in 2024 and averaged 14.14%.
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 54200bps in 2021, then plummeted by -82000bps in 2022.
  • BioNexus Gene Lab's Gross Margin (Quarter) stood at 14.7% in 2021, then fell by -19bps to 11.95% in 2022, then dropped by -2bps to 11.73% in 2023, then grew by 4bps to 12.25% in 2024, then grew by 21bps to 14.85% in 2025.
  • Its last three reported values are 14.85% in Q3 2025, 16.28% for Q2 2025, and 16.07% during Q1 2025.